JP Morgan Chase
AGN.PRA

JP Morgan Chase’s Allergan plc AGN.PRA Stock Holding History

JP Morgan Chase’s Portfolio AGN.PRA Stock Details AGN.PRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-70,404
Closed -$41.3M – 5793
2017
Q4 		$41.3M Buy
70,404
+27,490
+64% +$17.7M 0.01% 1084
2017
Q3 		$31.7M Buy
42,914
+1,929
+5% +$1.6M 0.01% 1200
2017
Q2 		$35.6M Buy
40,985
+2,326
+6% +$1.95M 0.01% 1093
2017
Q1 		$32.8M Sell
38,659
-25,335
-40% -$21M 0.01% 1155
2016
Q4 		$48.8M Sell
63,994
-2,470
-4% -$1.87M 0.01% 910
2016
Q3 		$54.6M Buy
66,464
+17,613
+36% +$15.2M 0.01% 791
2016
Q2 		$40.7M Sell
48,851
-373
-0.8% -$312K 0.01% 942
2016
Q1 		$45.2M Sell
49,224
-16,441
-25% -$15.7M 0.01% 862
2015
Q4 		$67.6M Buy
65,665
+14,424
+28% +$14.5M 0.02% 686
2015
Q3 		$48.3M Buy
51,241
+4,199
+9% +$4.38M 0.01% 794
2015
Q2 		$49.2M Buy
+47,042
New +$49.2M 0.01% 881

Other funds holding AGN.PRA

PWS
Peloton Wealth Strategists Indianapolis, Indiana $271M AUM 19.14% 1-Year Est. Return

JP Morgan Chase's AGN.PRA Position: Q1 2018 in Review

JP Morgan Chase sold out of Allergan plc (AGN.PRA) in Q1 2018, closing a stake of 70,404 shares — an estimated $41.3M sold.

JP Morgan Chase first reported a position in AGN.PRA in Q2 2015 and held it in 11 quarters. The position peaked at $67.6M in Q4 2015. 1 fund tracked by Wall St. Rank holds AGN.PRA as of Q1 2018.

  • JP Morgan Chase reported no remaining Allergan plc position as of Q1 2018 after selling out during the quarter.
  • JP Morgan Chase sold 70,404 Allergan plc shares in Q1 2018, an estimated $41.3M.
  • JP Morgan Chase first reported a position in Allergan plc in Q2 2015 and held it in 11 quarters.
  • JP Morgan Chase's Allergan plc position peaked at $67.6M in Q4 2015.
  • 1 fund tracked by Wall St. Rank held Allergan plc as of Q1 2018.

Based on JP Morgan Chase's 13F filing for Q1 2018, filed 10 May 2018.